Cloroqualoneis a quinazolinone-classGABAergicand is an analogue ofmethaqualonedeveloped in the 1980s and marketed mainly in France and some other European countries. It hassedativeandantitussiveproperties resulting from its agonist activity at the β subtype of theGABAareceptorandsigma-1 receptor,and was sold either alone or in combination with other ingredients as acough medicine.Cloroqualone has weaker sedative properties than methaqualone and was sold for its useful cough-suppressing effects, but was withdrawn from the French market in 1994 because of concerns about its potential for abuse and overdose.[1][2][3]
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | ? |
ATC code |
|
Pharmacokineticdata | |
Bioavailability | ? |
Metabolism | ? |
Eliminationhalf-life | ? |
Excretion | ? |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.042.761 |
Chemical and physical data | |
Formula | C16H12Cl2N2O |
Molar mass | 319.19g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?)(verify) |
See also
editReferences
edit- ^"Cloroqualone".PubChem.U.S. National Library of Medicine.Retrieved2022-07-29.
- ^Elks J (November 2014).The Dictionary of Drugs: Chemical Data.Springer US. p. 304.ISBN978-1-4757-2085-3.
- ^Martindale W, Reynolds JE (1993).Martindale: The Extra Pharmacopoeia(30th ed.). London: The Pharmaceutical Press. p. 745.ISBN978-0-85369-300-0.